Underlying business recovers, full-year earnings outlook reiterated
29/07/21 -"In its first Litmus test after an ‘ambitious’ CMD in June 2021, the British giant has put up a decent show. The group witnessed recovery in the base business, particularly in vaccines which benefited ..."
Pages
70
Language
English
Published on
29/07/21
You may also be interested by these reports :
09/07/25
After integrating the latest figures, we have refined our profitability expectations for the coming years. Given the robust business model, we ...
01/07/25
Back in late-2023, when Sanofi abandoned its 2025 profitability targets to step up its internal R&D efforts, the management had highlighted 12 ...
26/06/25
Downside for 1H25E consensus – FY25E consensus should be fine – Mid-term potential reiterated
24/06/25
Just like Big Pharmas in aggregate, Sanofi’s (Buy; France) shares have gone nowhere over the last two years. After collapsing by c.19% in a day in ...